U.S. markets open in 3 hours 27 minutes
  • S&P Futures

    4,078.00
    -3.25 (-0.08%)
     
  • Dow Futures

    34,544.00
    -55.00 (-0.16%)
     
  • Nasdaq Futures

    12,014.00
    -28.25 (-0.23%)
     
  • Russell 2000 Futures

    1,891.80
    +4.30 (+0.23%)
     
  • Crude Oil

    80.98
    +0.43 (+0.53%)
     
  • Gold

    1,791.90
    +32.00 (+1.82%)
     
  • Silver

    22.29
    +0.51 (+2.34%)
     
  • EUR/USD

    1.0422
    +0.0014 (+0.14%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • Vix

    20.92
    -0.97 (-4.43%)
     
  • GBP/USD

    1.2140
    +0.0078 (+0.64%)
     
  • USD/JPY

    136.3900
    -1.6900 (-1.22%)
     
  • BTC-USD

    17,099.87
    +221.87 (+1.31%)
     
  • CMC Crypto 200

    404.99
    +4.29 (+1.07%)
     
  • FTSE 100

    7,582.07
    +9.02 (+0.12%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Why Agenus Stock Rose 18.4% on Thursday

Why Agenus Stock Rose 18.4% on Thursday

Shares of Agenus (NASDAQ: AGEN), a clinical-stage biopharmaceutical company that specializes in immuno-oncology, saw its shares jump 18.4% on Thursday. First, the company on Wednesday said it planned to present data on botensilimab, a therapy that is being studied for its effectiveness as a combination drug or a monotherapy to active T-cell immune responses in patients who have pancreatic cancer, colorectal cancer, or melanoma, a type of skin cancer. Another move that helped push up the stock was the announcement of inside buying of Agenus stock by some members of the company's board of directors on Wednesday, including Susan Hirsch, Wadih Jordan, Ulf Wiinberg, and Timothy Wright, totaling more than 30,000 Agenus shares.